Trials / Unknown
UnknownNCT03535753
Safety and Efficacy Evaluation of Decitabine With R-GDP
Safety and Efficacy Evaluation of Decitabine With R-GDP on Refractory or Relapsed NHL Patients
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Assessment of the Safety and efficacy of Administering decitabin plus R-GDP to NHL patients
Detailed description
RR NHL patients will be treated with decitabin plus R-GDP , safety and efficacy will be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Decitabine and R-GDP | Decitabine and R-GDP |
Timeline
- Start date
- 2017-09-01
- Primary completion
- 2020-09-01
- Completion
- 2020-11-01
- First posted
- 2018-05-24
- Last updated
- 2018-05-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03535753. Inclusion in this directory is not an endorsement.